Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
3081-3100 of 3,900 trials

Bronchopulmonary Dysplasia: Stem Cell Treatment for Preterm Infants

We are studying the safety of umbilical cord stem cells in preterm babies with bronchopulmonary dysplasia. This research aims to see if the treatment can help improve their lung health and overall development.

Bronchopulmonary Dysplasia>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPediatricsPulmonology

Cholangiocarcinoma: SIRT and Capecitabine Study

We are evaluating a new treatment combining radiation therapy and chemotherapy for patients with operable intrahepatic cholangiocarcinoma. This study aims to see if this combination helps improve treatment outcomes before surgery.

Intrahepatic Cholangiocarcinoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Generalized Anxiety Disorder: ITI-1284 Treatment Study

We are evaluating the safety and effectiveness of a new medication, ITI-1284, for people with Generalized Anxiety Disorder who haven't found relief with current treatments. This study compares ITI-1284 to a placebo to see how well it works.

Generalized Anxiety Disorder≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPsychiatry

Granulomatosis with Polyangiitis: New Salvage Therapies

We are testing different treatment combinations for patients who haven't responded to standard care for granulomatosis with polyangiitis. The goal is to find the most effective way to help induce remission and improve overall health.

Granulomatosis with Polyangiitis (GPA)1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

Eosinophilic Esophagitis: EP 104GI Treatment Study

We are testing a new treatment called EP 104GI for adults with eosinophilic esophagitis. The study aims to evaluate its safety and effectiveness in reducing symptoms and improving esophageal health.

Eosinophilic Esophagitis1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesAllergologyGastroenterology

Rheumatoid Arthritis: Targeted Therapy vs. Triple Therapy

We are studying whether targeted therapies are more effective than a combination of three other medications for patients with rheumatoid arthritis who haven't responded to standard treatments. The trial also looks at safety and quality of life.

Rheumatoid ArthritisConfirmation phase (III)Monitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

COPD: Atorvastatin for Reducing Exacerbations

We are studying whether atorvastatin can help reduce flare-ups in smokers with chronic obstructive pulmonary disease. The trial also looks at how this medication may affect lung function and quality of life.

Chronic Obstructive Pulmonary Disease>2 yearsConfirmation phase (III)Standard MedicinesInternal MedicinePulmonology

Sjögren's Syndrome: Stem Cell Treatment for Dry Mouth

We are studying whether injecting stem cells into the salivary glands can improve saliva flow in patients with dry mouth from Sjögren's syndrome. This trial will also assess safety and other effects on saliva quality.

Sjögren's Syndrome≤3 monthsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesOrthopedics and TraumatologyRheumatology

Sublingual Vaccine: Trained Immunity Study

We are investigating whether a new sublingual vaccine can boost the immune system's response in blood cells. This study aims to understand its effects on trained immunity.

Healthy Participants>2 yearsSafety phase (I)Efficacy phase (II)

Endometrial Cancer: New Treatment Combination

We are studying a new combination of a dual mTOR inhibitor and anastrozole for women with metastatic hormone receptor-positive endometrial cancer. The goal is to see if this combination works better than anastrozole alone.

Advanced and Metastatic CancerSafety phase (I)Efficacy phase (II)Gynecology and ObstetricsOncology

Imlifidase for Severe ANCA-associated Vasculitis

We are studying whether imlifidase, combined with standard care, can improve outcomes for patients with severe ANCA-associated vasculitis and pulmonary hemorrhage. The trial will also assess its safety and effects on health markers.

ANCA-Associated Vasculitis3-6 monthsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPulmonologyRheumatology

MMRd Uterine Cancer: Pembrolizumab Treatment Study

We are investigating whether pembrolizumab can effectively treat MMRd uterine cancer before surgery. The study will assess how well it works and its safety for patients.

Endometrial Cancer1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGynecology and ObstetricsOncology

Hepatocellular Carcinoma: NMS-01940153E and Atezolizumab Study

We are studying a new treatment combination for adults with unresectable hepatocellular carcinoma who have been treated with other anti-cancer medicines. The goal is to see how well this combination works and its safety compared to existing options.

Unresectable Hepatocellular CarcinomaEfficacy phase (II)No PlaceboInvestigational MedicinesHepatologyOncology

Multiple Sclerosis: IMU-838 Treatment Study

We are investigating the effects of a new medication, IMU-838, on disease activity in people with relapsing-remitting multiple sclerosis. This study aims to understand how well it works and how safe it is compared to a placebo.

Relapsing-Remitting Multiple Sclerosis3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Hemophilia A: Innovative Treatment Approaches for Patients with Inhibitors

We are exploring various treatment methods for individuals with Hemophilia A who have inhibitors. The goal is to see how well these treatments reduce bleeding and improve health outcomes.

Hemophilia A>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesHematology

Cutaneous Lupus Erythematosus: IMVT-1402 Study

We are evaluating a new treatment for people with active cutaneous lupus erythematosus to see if it improves skin symptoms compared to a placebo. This study aims to assess its safety and effectiveness.

Skin Lupus1-2 yearsEfficacy phase (II)Investigational MedicinesCost ReimbursementDermatologyRheumatology

Multiple Myeloma: [68Ga]Ga-PentixaFor Imaging Study

We are exploring a new imaging method to see how well it detects multiple myeloma lesions in patients at diagnosis or relapse. This study may help improve the way we monitor and treat this condition.

Multiple Myeloma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Setmelanotide for ROHHAD Syndrome

We are studying the effects of setmelanotide on hypothalamic function and related symptoms in patients with ROHHAD syndrome. This trial aims to understand how the treatment may improve various health aspects over time.

ROHHAD Syndrome1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteEndocrinologyInternal Medicine

Pulmonary Arterial Hypertension: Inhaled GB002 Study

We are evaluating the long-term safety and effects of an inhaled medication for people with pulmonary arterial hypertension. The study aims to see if it helps improve exercise capacity and overall well-being.

Pulmonary Arterial Hypertension>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPulmonology

COVID-19 Booster: CD40.Pan.CoV Vaccine

We are testing a new vaccine to see if it safely boosts immunity in adults. This study will help us understand its effectiveness as a booster shot.

Healthy Participants1-2 yearsSafety phase (I)Infectious Diseases